GlassScriptPhysician profile
Michelle E Melisko
NPI 1306803812
$16,946.45
in general payments reported to CMS, 2019-2025
13 companies · $875 in 2025
The $875 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $3,188 · 2021: $2,848 · 2022: $2,931 · 2023: $2,635 · 2024: $4,096 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,358 · Food and Beverage: $1,235 · Education: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,357.50 |
| Food and Beverage | $1,235.25 |
| Education | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,246.62 | 2019-2024 | Itovebi, Phesgo |
| Astrazeneca Pharmaceuticals LP | $3,601.66 | 2021-2025 | Enhertu |
| Eisai INC. | $2,187.50 | 2020 | |
| Puma Biotechnology, INC. | $2,162.05 | 2019-2023 | |
| Daiichi Sankyo INC. | $1,850.96 | 2023-2024 | Enhertu |
| Astrazeneca Uk Limited | $1,712.50 | 2021 | |
| Gilead Sciences, INC. | $563.25 | 2021-2025 | Trodelvy |
| Stemline Therapeutics INC. | $187.58 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Pfizer INC. | $133.26 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $126.07 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Melisko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.